Drug Profile
Research programme: antibody-drug conjugate therapeutics - AbbVie/CytomX Therapeutics
Alternative Names: CX-2016; CX-2018; CX-2019Latest Information Update: 19 Jul 2023
Price :
$50
*
At a glance
- Originator CytomX Therapeutics
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Jul 2023 Preclinical development is ongoing in USA
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 09 May 2018 CytomX Therapeutics plans the phase I/II PROCLAIM-CX-2029 trial for Cancer (Metastatic disease, Late-stage disease, Monotherapy, Second-line therapy or greater) in USA in June 2018 (NCT03543813)